March 6th 2024
“Ultimately, we’re going to be able to see more patients, offer more precise surgery more efficiently, and that means just better outcomes for our patients here in the Intermountain West,” said Hilary McCrary, MD, MPH
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Increased Risk of Second Malignancies With Radioactive Iodine Therapy for Thyroid Cancer
April 27th 2015A new population-based study has found that patients with thyroid cancer who are treated with radioactive iodine therapy are at increased risk for developing salivary cancer as a second malignancy.
ASCO: Sorafenib Slows Progression in Advanced Thyroid Cancer
June 10th 2013Data presented at ASCO from the phase III DECISION trial showed treatment with the TKI sorafenib (Nexavar) delayed disease progression by 5 months in patients with metastatic differentiated thyroid cancer that had progressed on radioactive iodine.
Toward Improved Outcomes in Patients With Anaplastic Thyroid Cancer
April 17th 2012Like Burnison and Lim, we conclude conveying our sense of optimism that progress is being made-and that important clinical questions are being asked related to the care of patients afflicted with ATC. We believe, however, that in the final analysis, important progress will remain highly dependant upon collaborations conducted across specialties, across institutions, and across nations.
Multimodal Approach to Anaplastic Thyroid Cancer
April 15th 2012In this article, we endeavor to clarify the role of radiation therapy and chemotherapy in the treatment of ATC; we note important contributions of the historical literature, and we review more contemporary strategies adopted by several renowned institutions.
Vandetanib Now Available to U.S. Patients with Advanced Medullary Thyroid Cancer
April 25th 2011AstraZeneca today announced that the orphan drug vandetanib is now available to U.S. patients for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.
Will those exposed receive any immediate benefits from taking potassium iodide pills now?
March 16th 2011In response to the radiation spreading from the No. 3 reactor of the Fukushima Daiichi nuclear complex in Japan, sales of potassium iodide have soared. Some have claimed, however, that the short-term benefits of the drug are a myth, as the radioiodine is less likely to be inhaled, and more likely to be ingested in the future, often from drinking milk produced from cows grazing in areas affected by radiation fallout.
Pazopanib Holds Promise in Advanced Thyroid Cancers
November 29th 2010Pazopanib represents a therapeutic option for patients with advanced differentiated thyroid cancers. A phase II trial conducted at the Mayo Clinic in Rochester, Minn., included 39 patients with metastatic, rapidly progressive, radioiodine-refractory differentiated thyroid cancers.